-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
2 views
Headwinds galore from regulatory scrutiny, Medicare Advantage costs, and management changes, but insiders are buying, and the valuation is historically cheap. Q2 earnings are likely to be the trough. Clarity on regulatory scrutiny and the potential for renewed share buybacks or guidance could be catalysts for the stock post-earnings.
